Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

LYRA vs NVCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVCT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–0 Matrix Metrics)

NVCT Overall Winner 6-Pillar Tally: LYRA 2 – 3 NVCT (1 Tie) Matrix Metrics: LYRA 0 – 7 NVCT

As of Nov 17, 2026, Nuvectis Pharma, Inc. (NVCT) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas NVCT carries 53.4/100 (HOLD) at $19.07 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile NVCT is in a Breakdown options structure phase (RSI 46.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LYRA vs NVCT
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82
NVCT NASDAQ Head-to-Head Winner
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.07
-0.21% 1D
Market Cap $696.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.70β · 82% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 58.0 Fund 59.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $19.57 · SMA50: $20.40

6-Pillar Scorecard Institutional Category Breakdown (LYRA 2 – 3 NVCT)

Columns: Metric · LYRA · NVCT
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x N/M
2. Growth & Scale NVCT
Revenue Growth (YoY) -87.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $600,000 N/A
Market Cap $2.3M $696.0M
3. Profitability & Quality NVCT
Gross Margin N/A N/A
Operating Margin -25032.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -404.5% -67.0%
4. Balance Sheet & Cash Flow LYRA
Cash Generation (TTM) -$32M EBITDA -$40M
Cash Flow Margin N/A N/A
Net Cash / Leverage -404.5% ROE $3.68 Book/Sh · -67.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NVCT
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 72.4% (9th %ile)
Put/Call OI Skew N/A 6.68x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LYRA (0) vs NVCT (7)
Institutional Metric LYRA NVCT Criterion Row Edge
Market Capitalization
Scale
$2.3M $696.0M Larger Scale NVCT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-87.2% +0.0% Higher Growth NVCT
Operating Margin (TTM)
Profitability
-25032.0% 0.0% Higher Margin NVCT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-404.5% -67.0% Higher ROE NVCT
52-Week Range Position
Momentum
1% ($0–$38) 57% ($6–$29) Stronger Trend NVCT
Beta / 30D Volatility
Risk Regime
0.33β · 248% Vol 0.70β · 82% Vol Lower Realized Risk NVCT
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 53.4 / 100 (HOLD) Higher Composite NVCT
Trailing 12M Revenue (USD)
Operating Scale
$600,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M EBITDA (-404.5% ROE) -$40M ($3.68 Book/Sh · -67.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVCT +64.66 pp
LYRA: -62.5% · NVCT: +2.16%
3M Horizon NVCT +106.22 pp
LYRA: -87.62% · NVCT: +18.6%
6M Horizon NVCT +136.48 pp
LYRA: -87.14% · NVCT: +49.34%
1Y Horizon NVCT +136.48 pp
LYRA: -87.14% · NVCT: +49.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LYRA vs NVCT. Trailing 12-month operating profitability (LYRA -25032.0% vs NVCT 0.0%) and valuation multiples (LYRA N/M vs NVCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LYRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$600,000
Gross MarginN/A
Op. Margin-25032.0%
ROE / Fwd P/E-404.5% · N/M
NVCT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-67.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVCT BREAKDOWN
99d in phase · OBV NEUTRAL
Current IV 72.4%
IV Percentile 9th %ile
Put/Call OI Skew 6.68x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact NVCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NVCT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $696.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LYRA vs NVCT Key Questions & Quantitative Answers

As of Nov 17, 2026, Nuvectis Pharma, Inc. (NVCT) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas NVCT carries 53.4/100 (HOLD) at $19.07 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile NVCT is in a Breakdown options structure phase (RSI 46.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NVCT leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with NVCT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LYRA generates $600,000 in USD-normalized revenue versus N/A for NVCT. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NVCT.

LYRA screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas NVCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus NVCT (-67.0% ROE) capital efficiency.

In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, NVCT carries 72.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 6.68x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.70β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.